eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Companyâ€™s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
08/06/26	0.000200 $	0.00%	978
05/06/26	0.000200 $	0.00%	2,640

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 15:32:15 08/06/2026 BST			5-day change	1st Jan Change
0.000200 ^USD	0.00%		0.00%	-

10/09/24	Tyra Biosciences Names Doug Warner Chief Medical Officer	MT
07/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index	CI

Market Cap	940 812.67 748.62 701.18 1.31K 89.39K 1.33K 8.87K 3.45K 43.48K 3.53K 3.45K 151K	P/E Ratio 2022	-0.78x	P/E Ratio 2023	-0.71x
Enterprise Value	2.18M 1.88M 1.73M 1.62M 3.04M 207M 3.09M 20.53M 7.98M 101M 8.17M 7.99M 349M	EV / Sales 2022	3,344,920x	EV / Sales 2023	-
Free-Float	99.75%	Yield 2022 *	-	Yield 2023	-

10/09/24	Tyra Biosciences Names Doug Warner Chief Medical Officer	MT
07/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index	CI
01/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index	CI
24/06/24	Sector Update: Health Care Stocks Rise in Late Afternoon Trading	MT
24/06/24	Top Midday Decliners	MT
24/06/24	EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives	MT
24/06/24	EFFECTOR Therapeutics, Inc. Announces Cessation of Michael Byrnes, Chief Financial Officer	CI
24/06/24	Effector Therapeutics, Inc. Terminates Its Employees in Connection with the Planned Wind Down of the Company?s Operations	CI
24/06/24	Effector Therapeutics, Inc. Announces Director Resignations	CI
24/06/24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as CEO	CI
24/06/24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board	CI
20/05/24	EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer	CI
09/05/24	EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

24/08/23	HC Wainwright Starts eFFECTOR Therapeutics With Buy Rating, $5 Price Target	MT
26/05/23	Stifel Upgrades eFFECTOR Therapeutics to Buy From Hold, Adjusts Price Target to $7 From $1.30	MT
10/05/23	Credit Suisse Trims eFFECTOR Therapeutics' Price Target to $5.50 From $7, Keeps Outperform Rating	MT
09/03/23	Credit Suisse Adjusts eFFECTOR Therapeutics' Price Target to $7 From $8, Keeps Outperform Rating	MT
09/01/23	JMP Securities Trims Price Target on eFFECTOR Therapeutics to $1 From $2, Maintains Market Outperform Rating	MT

eFFECTOR Therapeutics, Inc. Share Price

Stocks

EFTR

US28202V2079

Biotechnology & Medical Research

Valuation: eFFECTOR Therapeutics, Inc.

Chart: eFFECTOR Therapeutics, Inc.

Latest news : eFFECTOR Therapeutics, Inc.

Analysts' recommendations: eFFECTOR Therapeutics, Inc.

Press Releases: eFFECTOR Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: eFFECTOR Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

13/08/24	FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer	AQ
26/06/24	EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K	PU
24/06/24	EFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq	AQ
04/04/24	EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	AQ
05/02/24	EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	AQ

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.02
3 years	0		31.5
5 years	0		1,010.5
10 years	0		1,010.5

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/06/24	Brian Gallagher	Free	Chairman	800	0.0170%
12/06/24	Elizabeth Bhatt	Free	Director	800	0.0170%
12/06/24	Christopher Ehrlich	Free	Director	800	0.0170%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EFFECTOR THERAPEUTICS, INC.	0.00%	0.00%	0.00%	-100.00%	940
ARGENX SE	+1.03%	+7.52%	+54.74%	+114.98%	55.58B
WUXI APPTEC CO., LTD.	+2.72%	+3.06%	+53.28%	+47.85%	43.47B
BIONTECH SE	+1.12%	+1.06%	-14.15%	-17.13%	22.64B
INSMED INCORPORATED	+1.17%	-6.74%	-0.13%	+394.19%	20.96B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-4.13%	+16.62%	-30.70%	15.79B
GENMAB A/S	+0.15%	+2.24%	+9.06%	-39.50%	15.3B
EXELIXIS, INC.	-0.69%	+1.22%	+28.24%	+176.72%	13.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+6.41%	+21.05%	-	11.74B
PHARMAESSENTIA CORPORATION	+1.61%	+1.17%	+90.79%	+212.97%	10.96B
Average	+1.62%	+0.23%	+25.95%	+84.38%	20.99B
Weighted average by Cap.	+1.71%	+1.60%	+33.63%	+100.77%

	2022	2023
Net sales	3.55 3.07 2.83 2.65 4.97 337.89 5.04 33.53 13.03 164.36 13.33 13.05 569.14	-
Net income	-22.66M -19.59M -18.05M -16.91M -31.7M -2.16B -32.18M -214M -83.09M -1.05B -85.06M -83.24M -3.63B	-35.81M -30.96M -28.52M -26.71M -50.09M -3.41B -50.85M -338M -131M -1.66B -134M -132M -5.74B
Net Debt	-6.03M -5.21M -4.8M -4.5M -8.43M -573M -8.56M -56.89M -22.1M -279M -22.63M -22.14M -966M	2.18M 1.88M 1.73M 1.62M 3.04M 207M 3.09M 20.52M 7.97M 101M 8.16M 7.99M 348M